Literature DB >> 540036

Quantitative N-terminal analysis of fibrinogen-fibrin-related antigen [FR antigen] from human plasma.

J U Harris, A J Johnson, C Merskey, M T Wang, D Robinson.   

Abstract

Fibrinogen-fibrin-related antigen (FR antigen) was isolated from as little as 1 ml of human plasma by immuno-affinity chromatography with agarose-bound antibody to human fibrinogen. N-terminal analysis was performed to determine the nature and extent of proteolytic degradation of the FR antigen in patients with disseminated intravascular coagulation and in normal subjects. Thrombin cleavage of the A- and B-peptides from fibrinogen in vitro was monitored by the appearance of N-terminal glycine, and an increase in glycine was shown in the FR antigen of patients with disseminated intravascular coagulation. As plasmin progressively degraded fibrinogen, increases in N-terminal alanine, aspartic acid and lysine were observed, corresponding to the known plasmin-cleavage points of fibrinogen; increases in these N-terminal amino acids were also found in the patients' FR antigen. Thrombin treatment in vitro was used to remove fibrinopeptide A (N-terminal alanine) from the samples and to reflect specifically the N-terminal alanine at the plasmin-cleavage point (Arg-42-Ala-43) of the B beta-chain on assay; this alanine was increased progressively in the FR antigen of a patient during urokinase therapy, and was high in other patients when the FR antigen was examined by this procedure.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 540036      PMCID: PMC1161644          DOI: 10.1042/bj1830623

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  23 in total

1.  Terminal amino acids of human and bovine gamma globulin.

Authors:  W P LAY; W J POLGLASE
Journal:  Can J Biochem Physiol       Date:  1957-01

Review 2.  Disseminated intravascular coagulation: a review.

Authors:  P J Hamilton; A L Stalker; A S Douglas
Journal:  J Clin Pathol       Date:  1978-07       Impact factor: 3.411

3.  Amino-terminal sequence analysis of proteins purified on a nanomole scale by gel electrophoresis.

Authors:  A M Weiner; T Platt; K Weber
Journal:  J Biol Chem       Date:  1972-05-25       Impact factor: 5.157

Review 4.  The molecular structure of fibrinogen.

Authors:  B Blombäck; M Blombäck
Journal:  Ann N Y Acad Sci       Date:  1972-12-08       Impact factor: 5.691

5.  The effect of plasmin on the subunit structure of human fibrin.

Authors:  S V Pizzo; M L Schwartz; R L Hill; P A McKee
Journal:  J Biol Chem       Date:  1973-07-10       Impact factor: 5.157

6.  Heterogeneity of human fibrinogen: possible relation to proteolysis by thrombin and plasmin as studies by SDS-polyacrylamide gel electrophoresis.

Authors:  D Mills; S Karpatkin
Journal:  Biochem Biophys Res Commun       Date:  1970-07-13       Impact factor: 3.575

7.  Studies on soluble fibrin in plasma. I. N-terminal analysis of a modified fraction I (Cohn) from normal and thrombin-incubated plasma.

Authors:  P Kierulf; U Abildgaard
Journal:  Scand J Clin Lab Invest       Date:  1971-10       Impact factor: 1.713

8.  Rapid analysis of amino acid phenylthiohydantoins by high-performance liquid chromatography.

Authors:  C L Zimmerman; E Appella; J J Pisano
Journal:  Anal Biochem       Date:  1977-02       Impact factor: 3.365

9.  Preparation of the major plasma fractions by solid-phase polyelectrolytes.

Authors:  A J Johnson; V E MacDonald; M Semar; J E Fields; J C Schuck; J Brind
Journal:  J Lab Clin Med       Date:  1978-08

10.  The preparation and properties of human fibrinogen of relatively high solubility.

Authors:  M W Mosesson; S Sherry
Journal:  Biochemistry       Date:  1966-09       Impact factor: 3.162

View more
  1 in total

1.  Fibrinogen Stony Brook, a heterozygous A alpha 16Arg----Cys dysfibrinogenemia. Evaluation of diminished platelet aggregation support and of enhanced inhibition of fibrin assembly.

Authors:  D K Galanakis; A Henschen; E I Peerschke; M Kehl
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.